Gerald Willimsky

4.2k citations

49 papers · 2.0k indexed · 1 hit paper · h-index 23

Immunology top 2%
- Immunotherapy and Immune Responses 29
- Immune Cell Function and Interaction 16
- T-cell and B-cell Immunology 7
- Immune cells in cancer 4
Oncology top 5%
- CAR-T cell therapy research 17
- Cancer Immunotherapy and Biomarkers 13
Biotechnology top 5%
Molecular Biology
- vaccines and immunoinformatics approaches 5
Genetics top 10%
- Virus-based gene therapy research 9

Co-authors: Thomas Blankenstein Mohamed A. Marahiel Holger Bang G. Fischer Shabnam Shalapour Peter Birner Donna E. Hansel Giuseppe Di
Cited by: Immunology Oncology Biotechnology
Journals: Human Gene Therapy (3 papers)Frontiers in Immunology (3 papers)Gene Therapy (3 papers)
Partner nations: Germany United States Croatia

In The Last Decade

Gerald Willimsky

48 papers receiving 2.0k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Gerald Willimsky

Since Specialization

Citations

This map shows the geographic impact of Gerald Willimsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald Willimsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald Willimsky more than expected).

Fields of papers citing papers by Gerald Willimsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald Willimsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald Willimsky. The network helps show where Gerald Willimsky may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Gerald Willimsky, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gerald Willimsky Line = papers co-authored together Gerald Willimsky links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire Journal for ImmunoTherapy of Cancer ·郑亚惠,Leo Hansmann,Shaomin Zhang,邢凯旋,直彦矢谷,麦珏昉,Jinyong Li,Guoshuai Cao,Jun Huang,Poh Yin Yew,Erlend Strønen,Taigo Kato,Naresha Saligrama,Johanna Olweus,Yusuke Nakamura,Gerald Willimsky,Thomas Blankenstein,Hans Schreiber,Matthias Leisegang	2025	2
2	A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies Blood ·正勝土田,Chiao-Chih Lin,昌洋吉岡,G. G. MIKAELYAN,강호원,Matthias Leisegang,V. Korotkikh,沈栖,Cäcilia Freund,Gerald Willimsky,Frank Konietschke,Elisa Kieback,Sarah K. Tasian,Bjoern Chapuy,Ulrich Keller,Thomas Blankenstein,Antonio Pezzutto,Antonia Busse	2025	0
3	A facility for laboratory mice with a natural microbiome at Charité – Universitätsmedizin Berlin Lab Animal ·Natascha Drude,رضا فرتوت زاده,Stephan P. Rosshart,Andreas Diefenbach,Kai Diederich,Claudia U. Duerr,Christoph Harms,Frank L. Heppner,Marina Kolesnichenko,Lars Lewejohann,Marcus Mall,Dominik N. Müller,Bastian Opitz,Gilbert Schönfelder,Jens Larsen,Gerald Willimsky,Stefan Jordan	2024	1
4	Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptors Frontiers in Immunology ·General John Hardy,George Papafotiou,Tourouzou Herver Some,T. Wiklind,Annette Paschen,Thomas Blankenstein,Gerald Willimsky	2023	3
5	EBAG9 controls CD8+ T cell memory formation responding to tumor challenge in mice JCI Insight ·Armin Rehm,Luís Tadeu Assad,洋司宮里,Cornelius Fischer,Azadeh Faridi,Kerstin Gerlach,Sascha Sauer,Gerald Willimsky,Uta E. Höpken	2022	2
6	H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2⁺ patients with diffuse midline glioma Journal for ImmunoTherapy of Cancer ·General John Hardy,George Papafotiou,Oliver Popp,Philipp Mertins,Thomas Blankenstein,Gerald Willimsky	2022	11
7	Isolation of Neoantigen-Specific Human T Cell Receptors from Different Human and Murine Repertoires Cancers ·昌洋吉岡,Gerald Willimsky,W. Leonor,正勝土田,Leo Hansmann,Thomas Blankenstein,Eric Blanc,Dieter Beule,Ulrich Keller,Antonio Pezzutto,Antonia Busse	2022	2
8	Lymphocyte access to lymphoma is impaired by high endothelial venule regression Cell Reports ·Lutz Menzel,Caroline Aalbers,Mayerlin P. Jaimes Materano,Vedran Franke,Michael Grau,Flight Tests,Anja E. Hauser,Volker Siffrin,Marc Bajénoff,Dimitrios Papandreou,Altuna Akalin,Georg Lenz,Gerald Willimsky,Uta E. Höpken,Armin Rehm	2021	12
9	In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo eLife ·Gerald Willimsky,Ewa Sobolewska,General John Hardy,George Papafotiou,T. Wiklind,Andrean Goede,Hermann−Georg Holzhütter,Thomas Blankenstein,Peter M. Kloetzel	2021	12
10	ERAP1-Dependent Antigen Cross-Presentation Determines Efficacy of Adoptive T-cell Therapy in Mice Cancer Research ·Divyang Solanki,Christin Keller,Anja A. Kühl,Ana Textor,Ulrike Seifert,Thomas Blankenstein,Gerald Willimsky,Peter‐Michael Kloetzel	2018	11
11	Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus Clinical Cancer Research ·Ioannis Gavvovidis,Matthias Leisegang,Gerald Willimsky,Natalie Miller,Paul Nghiem,Thomas Blankenstein	2018	24
12	Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies—the German Cancer Consortium approach Cancer Immunology Immunotherapy ·Angela M. Krackhardt,Brigitte Anliker,Martin Hildebrandt,Michael Bachmann,Stefan B. Eichmüller,Dirk M. Nettelbeck,Matthias Renner,Lutz Uharek,Gerald Willimsky,Michael Schmitt,Winfried S. Wels,Martina Schüßler‐Lenz	2018	12
13	Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival Cancer Immunology Research ·Natalie Miller,Candice D. Church,Lichun Dong,David A. Crispin,Matthew Fitzgibbon,Kristina Lachance,Lichen Jing,Michi M. Shinohara,Ioannis Gavvovidis,Gerald Willimsky,Martin McIntosh,Thomas Blankenstein,David M. Koelle,Paul Nghiem	2017	71
14	Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy Cancer Research ·Ramona Schlenker,Bangli Peng,Matthias Leisegang,Pablo Delfini,Nolla Timmins,Svenja Rühland,Peter J. Nelson,Heinrich Leonhardt,Hartmann Harz,Susanne Wilde,Dolores J. Schendel,Wolfgang Uckert,Gerald Willimsky,Elfriede Noeßner	2017	33
15	Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapybreakdown → Nature ·Shabnam Shalapour,Joan Font-Burgada,Giuseppe Di,Zhenyu Zhong,Elsa Sánchez‐López,Debanjan Dhar,Gerald Willimsky,Massimo Ammirante,Amy Strasner,Donna E. Hansel,Christina Jamieson,Christopher J. Kane,Tobias Klatte,Peter Birner,Lukas Kenner,Michael Karin	2015	429
16	Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance Journal of Clinical Investigation ·Gerald Willimsky,Divyang Solanki,Christoph Loddenkemper,Johanna Gellermann,Thomas Blankenstein	2013	41
17	In Vivo Imaging of an Inducible Oncogenic Tumor Antigen Visualizes Tumor Progression and Predicts CTL Tolerance The Journal of Immunology ·Nobuyoshi OHYABU,Jehad Charo,Fritz B. Simon,Christoph Loddenkemper,奈生東儀,Banjob Bannaruji,Cynthia Pérez,Gerald Willimsky,Thomas Blankenstein	2010	12
18	Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness The Journal of Experimental Medicine ·Gerald Willimsky,Melinda Czéh,Christoph Loddenkemper,Johanna Gellermann,Divyang Solanki,Peter Wust,Harald Stein,Thomas Blankenstein	2008	88
19	Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse Gene Therapy ·D. J. Schendel,Bernhard Frankenberger,Antonio Victor Sousa Pereira,S Cayeux,Ma Chunhong,Gerald Willimsky,Saadi Abu Zaneh,Heike Pohla,T. Blankenstein	2000	33
20	Overproduction, crystallization, and preliminary X‐ray diffraction studies of the major cold shock protein from Bacillus subtilis, CspB Proteins Structure Function and Bioinformatics ·Hermann Schindelin,Michael Herrler,Gerald Willimsky,Mohamed A. Marahiel,Udo Heinemann	1992	43

About Gerald Willimsky

Gerald Willimsky is a scholar working on Immunology, Oncology and Virology, having authored 49 papers that have together received 2.0k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (29 papers), CAR-T cell therapy research (17 papers), Immune Cell Function and Interaction (16 papers), Cancer Immunotherapy and Biomarkers (13 papers), Virus-based gene therapy research (9 papers), T-cell and B-cell Immunology (7 papers), vaccines and immunoinformatics approaches (5 papers) and Immune cells in cancer (4 papers). The work is most often cited by research in Immunology (1.2k citations), Oncology (981 citations) and Biotechnology (95 citations). Gerald Willimsky has collaborated with scholars based in Germany, United States and Croatia. Frequent co-authors include Thomas Blankenstein, Mohamed A. Marahiel, Holger Bang, G. Fischer, Shabnam Shalapour, Peter Birner, Donna E. Hansel, Giuseppe Di, Lukas Kenner and Zhenyu Zhong. Their work appears in journals such as Human Gene Therapy, Frontiers in Immunology, Gene Therapy, Blood and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact